^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IDP-121

    i
    Other names: IDP-121, IDP 121
    Associations

    News

    Trials
    Company:
    IDP Discovery Pharma
    Drug class:
    MYC inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    CASSANDRA: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=37, Recruiting, IDP Discovery Pharma S.L. | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: May 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    IDP-121
    11ms
    CASSANDRA: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=37, Recruiting, IDP Discovery Pharma S.L.
    New P1/2 trial
    |
    IDP-121
    3years
    [VIRTUAL] A first-in-class c-MYC inhibitor shows in vivo efficacy in lung cancer models and has appropriate drug-like characteristics (AACR 2021)
    The efficacy in hematological tumors of IDP-121 have been also demonstrated in vivo (see Abstract 2). In addition, IDP-121 has progressed through GLP toxicology studies without evidence of major systemic toxicity, allowing for the first viable Myc-targeted therapy to enter Phase 1 clinical trials in 2021.
    Preclinical
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC expression
    |
    IDP-121